Neuronetics (STIM) News Today → Breaking News: Elon Musk Invents New Type of A.I. (Shocking) (From InvestorPlace) (Ad) Free STIM Stock Alerts $2.61 +0.09 (+3.57%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16 at 5:42 AM | americanbankingnews.comWilliam Blair Upgrades Neuronetics (NASDAQ:STIM) to OutperformMay 15 at 7:30 PM | msn.comWilliam Blair Upgrades Neuronetics (STIM)May 15 at 7:32 AM | globenewswire.comHumana Is First Commercial Payer to Address TMS Therapy Coverage for AdolescentsMay 14, 2024 | marketbeat.comNeuronetics (NASDAQ:STIM) Upgraded to "Outperform" at William BlairWilliam Blair raised shares of Neuronetics from a "market perform" rating to an "outperform" rating in a research note on Tuesday.May 11, 2024 | americanbankingnews.comQ2 2024 Earnings Estimate for Neuronetics, Inc. (NASDAQ:STIM) Issued By William BlairMay 10, 2024 | msn.comNeuronetics Boasts 12% Revenue Increase, Expands Depression Treatment SectorMay 10, 2024 | marketbeat.comQ2 2024 EPS Estimates for Neuronetics, Inc. Cut by William Blair (NASDAQ:STIM)Neuronetics, Inc. (NASDAQ:STIM - Free Report) - William Blair dropped their Q2 2024 earnings estimates for Neuronetics in a research note issued to investors on Tuesday, May 7th. William Blair analyst M. Kaczor now anticipates that the company will post earnings of ($0.27) per share for the quartMay 9, 2024 | finance.yahoo.comNeuronetics, Inc. (NASDAQ:STIM) First-Quarter Results: Here's What Analysts Are Forecasting For This YearMay 9, 2024 | seekingalpha.comNeuronetics: Reality Set InMay 8, 2024 | markets.businessinsider.comStrong Buy Rating for Neuronetics Backed by Solid Financials and Growth ProspectsMay 8, 2024 | finance.yahoo.comNeuronetics, Inc. (NASDAQ:STIM) Q1 2024 Earnings Call TranscriptMay 8, 2024 | markets.businessinsider.comBuy Rating on Neuronetics: Solid Fundamentals and Growth Despite ChallengesMay 8, 2024 | finance.yahoo.comNeuronetics Inc (STIM) (Q1 2024) Earnings Call Transcript Highlights: Strategic Growth Amidst ...May 8, 2024 | wsj.comNeuronetics Inc.May 7, 2024 | msn.comNeuronetics GAAP EPS of -$0.27 beats by $0.04, revenue of $17.42M beats by $0.3MMay 7, 2024 | msn.comSTIM Stock Earnings: Neuronetics Beats EPS, Beats Revenue for Q1 2024May 7, 2024 | finance.yahoo.comNeuronetics Inc (STIM) Reports Q1 2024 Earnings: Revenue Surpasses Estimates, Narrowing LossesMay 7, 2024 | globenewswire.comNeuronetics Reports Record First Quarter 2024 Financial and Operating ResultsMay 6, 2024 | msn.comNeuronetics Q1 2024 Earnings PreviewMay 4, 2024 | finance.yahoo.comNeuronetics, Inc. (STIM)May 4, 2024 | msn.comNeuronetics Awards Stock Options to New Employees as InducementMay 3, 2024 | globenewswire.comNeuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 1, 2024 | globenewswire.comNeuroStar® TMS Advances Treatment for Adolescents During Mental Health Awareness MonthApril 27, 2024 | marketbeat.comNeuronetics, Inc. (NASDAQ:STIM) Sees Large Drop in Short InterestNeuronetics, Inc. (NASDAQ:STIM - Get Free Report) saw a large decrease in short interest during the month of April. As of April 15th, there was short interest totalling 57,700 shares, a decrease of 39.0% from the March 31st total of 94,600 shares. Based on an average trading volume of 170,500 shares, the short-interest ratio is presently 0.3 days.April 25, 2024 | msn.comNeuronetics Announces Q1 2024 Earnings Release and Conference CallApril 23, 2024 | globenewswire.comNeuronetics to Report First Quarter 2024 Financial and Operating Results and Host Conference CallApril 12, 2024 | marketbeat.comShort Interest in Neuronetics, Inc. (NASDAQ:STIM) Rises By 77.8%Neuronetics, Inc. (NASDAQ:STIM - Get Free Report) saw a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 94,600 shares, a growth of 77.8% from the March 15th total of 53,200 shares. Based on an average trading volume of 199,100 shares, the days-to-cover ratio is currently 0.5 days.April 12, 2024 | msn.comNew Study Offers Hope for Depression Patients Undergoing TMS TherapyApril 10, 2024 | globenewswire.comNew Publication in Brain Stimulation Confirms Full TMS Treatment Course Is VitalApril 6, 2024 | marketbeat.comKent Lake Capital LLC Has $3.24 Million Stake in Neuronetics, Inc. (NASDAQ:STIM)Kent Lake Capital LLC decreased its stake in shares of Neuronetics, Inc. (NASDAQ:STIM - Free Report) by 52.1% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 1,116,041 shares of the company's stock after selling 1,213,246 shares during theApril 5, 2024 | benzinga.comNeuronetics Stock (NASDAQ:STIM), Quotes and News SummaryApril 1, 2024 | msn.comNeuronetics Bolsters Talent Pool with Strategic Stock Incentives for New HiresMarch 29, 2024 | msn.comFDA Clears NeuroStar's TMS Therapy for Adolescents with Major Depressive DisorderMarch 28, 2024 | marketbeat.comNeuronetics, Inc. (NASDAQ:STIM) Short Interest UpdateNeuronetics, Inc. (NASDAQ:STIM - Get Free Report) saw a significant decrease in short interest in the month of March. As of March 15th, there was short interest totalling 53,200 shares, a decrease of 64.9% from the February 29th total of 151,700 shares. Based on an average daily volume of 204,300 shares, the short-interest ratio is presently 0.3 days.March 27, 2024 | finance.yahoo.comNeuronetics wins FDA clearance for device to treat adolescents with depressionMarch 27, 2024 | finance.yahoo.comNeuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)March 27, 2024 | globenewswire.comNeuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)March 27, 2024 | markets.businessinsider.comBuy Rating for Neuronetics Amid FDA Clearance and Expanding Adolescent MDD MarketMarch 26, 2024 | marketbeat.comNeuronetics' (STIM) "Market Perform" Rating Reiterated at William BlairWilliam Blair reiterated a "market perform" rating on shares of Neuronetics in a report on Tuesday.March 25, 2024 | msn.comNeuronetics’s NeuroStar wins FDA clearance for adolescents with depressionMarch 25, 2024 | finanznachrichten.deNeuronetics: NeuroStar Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with DepressionMarch 25, 2024 | marketwatch.comNeuronetics Shares Climb 15% After FDA Cleared Depression Treatment for Adolescents Aged 15 to 21March 25, 2024 | markets.businessinsider.comNeuronetics: NeuroStar Advanced Therapy Gets FDA Clearance For New IndicationMarch 25, 2024 | globenewswire.comNeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with DepressionMarch 16, 2024 | finance.yahoo.comSTIM Apr 2024 5.000 putMarch 12, 2024 | msn.comNeuronetics and Transformations Care Network Join Forces to Expand Availability of Innovative Depression TreatmentMarch 7, 2024 | seekingalpha.comNeuronetics, Inc. (STIM) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | finance.yahoo.comNeuronetics Inc (STIM) Reports Record Revenues in Q4 and Full Year 2023March 7, 2024 | finance.yahoo.comNeuronetics, Inc. (NASDAQ:STIM) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | globenewswire.comNeuronetics Announces 5-Year Exclusive Partnership with Transformations Care Network Get Neuronetics News Delivered to You Automatically Sign up to receive the latest news and ratings for STIM and its competitors with MarketBeat's FREE daily newsletter. Email Address Elon Musk’s PRIME is Set to Shock the World (Ad)Must-See: Elon's New Invention is Absolutely Insane When you click here and see what Elon Musk’s new invention does…You will NOT believe it. But Elon just tested this in a real human… And the result was mind-blowing. Click here for the full story… STIM Media Mentions By Week STIM Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. STIM News Sentiment▼0.070.49▲Average Medical News Sentiment STIM News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. STIM Articles This Week▼62▲STIM Articles Average Week Get Neuronetics News Delivered to You Automatically Sign up to receive the latest news and ratings for STIM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: PDEX News Today NVNO News Today MGRM News Today SEPA News Today HSAQ News Today SRTS News Today NSPR News Today BWAY News Today DRIO News Today ICCM News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:STIM) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceNext President (Not Trump. Not Biden.)The Freeport SocietyWhat’s Really Next for America…Porter & CompanyExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersProtect Your Bank Account Before It’s Too LateWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuronetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
